Trulicity® (dulaglutide) and decreased appetite

Where decreased appetite is counted

The US label lists decreased appetite in its placebo-controlled table, which admits reactions reported by at least 5% on Trulicity® and more often than on placebo; in those studies people stayed on the dose they started with. ^[1] The Canadian Table 2 uses a 1% bar, counts every event that arose during treatment whatever the cause, and records weight loss as an event in its own right. ^[4] The EU summary gives a frequency class. ^[3]

Large ratio, small absolute numbers

Because so few people on placebo reported a smaller appetite, the relative difference looks large: about three times the placebo rate on 0.75 mg and more than five times on 1.5 mg. ^[1] In absolute terms, more than nine in ten people in these trials did not report it. The longer Canadian pool tells a similar story, with 7.7% on 1.5 mg against 2.1% on comparators. ^[4]

The 36-week trial of higher doses does not list decreased appetite, so it stayed under 5% in each group, and the label offers no figure to show whether it keeps rising above 1.5 mg. ^[1] The Canadian patient information places decreased appetite in its “common” band, between 1 in 100 and 1 in 10 people. ^[4]

What the trials show about weight

The label treats weight as a trial result rather than a side effect, and its approved uses are improving blood sugar and lowering the risk of major heart events in type 2 diabetes, not weight loss. ^[1] In the 52-week trial against sitagliptin, mean weight at 26 weeks fell by 2.7 kg on 0.75 mg and 3.0 kg on 1.5 mg, against 1.4 kg on both placebo and sitagliptin; in the higher-dose trial, 4.5 mg lowered weight significantly more than 1.5 mg. ^[1]

The EU summary reports weight changes across its studies ranging from a 0.35 kg to a 2.90 kg loss on 1.5 mg, and from a 0.86 kg gain to a 2.63 kg loss on 0.75 mg. In the higher-dose trial, 31%, 40% and 49% of people on 1.5 mg, 3 mg and 4.5 mg had lost at least 5% of their starting weight by week 36. ^[3] None of these figures measures appetite directly.

Research on appetite and diet

A 2026 meta-analysis pooled 101 randomised trials of five GLP-1 medicines, 18 of them testing dulaglutide. Decreased appetite was about 3.5 times as likely as on placebo, with a pooled incidence of 2.61% across the class; the abstract does not give a dulaglutide-only figure. ^[8]

A 2025 cross-sectional study in a diabetes clinic in Turin compared 52 adults on GLP-1 medicines, 40% of them on dulaglutide, with 51 on other diabetes tablets. Energy intake, the balance of carbohydrate, fat and protein, and adherence to a Mediterranean diet did not differ between the groups, and none of the GLP-1 users met fibre recommendations. The authors called for structured nutrition counselling alongside these medicines. ^[7] One small survey cannot show cause and effect, but it is a reminder that eating less is not the same as eating well.

Why appetite falls

• What the label supports: dulaglutide slows stomach emptying (section 12.1), and the EU leaflet lists feeling less hungry among its common effects. ^[1][3] MedlinePlus’s drug page says so directly: dulaglutide slows the emptying of the stomach and may decrease appetite and cause weight loss. ^[5]
• Suggested by the data, not measured: the EU observation that weight fell further in people with nausea hints that some of the drop in eating travels with feeling sick, but the summary does not measure appetite itself. ^[3] The Trulicity® nausea page covers that side effect in detail.
• General medical background: MedlinePlus notes that any illness can reduce appetite, and that appetite should return once a treatable illness is cured. ^[6]

Other reasons for eating less

MedlinePlus lists many causes of a reduced appetite. It is common in older adults, often without a physical cause being found. Sadness, depression or grief can play a part, as can chronic kidney or liver disease, heart failure, COPD, an underactive thyroid and dementia, some cancers that bring weight loss without trying, early pregnancy, and medicines such as antibiotics, codeine and morphine. ^[6]

A fall in appetite after starting Trulicity® is therefore worth a conversation rather than an assumption, especially if it continues. If low appetite comes with signs of depression, alcohol or drug use, or an eating disorder, MedlinePlus advises seeking medical help. ^[6]

Eating enough when hunger is low

MedlinePlus suggests several small meals or nutritious snacks through the day, having favourite foods within reach (relatives can help with this), and keeping a record of what you eat and drink for a day or longer to show your provider. If a medicine seems to be behind the loss of appetite, it suggests discussing the dose or the medicine with your provider, and it is clear that no medicine should be stopped without talking to them first. ^[6] The Medication Guide notes that Trulicity® can be taken with or without food, and asks you to drink fluids to lower the chance of dehydration. ^[2]

If you also use insulin or a sulfonylurea, eating less matters for blood sugar. The US label says the risk of low blood sugar rises with those medicines, and the EU leaflet says their dose may need to be lowered while you use dulaglutide; only your prescriber can make that change. ^[1][3] The broader guide to eating with a low appetite, linked below, covers meal ideas that are not specific to Trulicity®.

Trulicity® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help